Know what the readout has to prove — before it prints.
ClinicalInvestor turns FDA decision dates, clinical trial designs, and company pipelines into a plain-English checklist: what the bar is, what would count as a miss, and which risks the press release will not mention.
Edited by Blane Jackson, DDS, MBA under a published editorial policy and disclosures. Educational research, not investment advice.
27
Upcoming catalysts tracked
24
Company profiles
7
Monthly calendars published
2026-09-09
Catalyst data last updated
Counts are generated from published content at build time, not estimated. How we build this.
Trial Translator
Free toolPaste any ClinicalTrials.gov ID and get an instant plain-English breakdown — live registry data plus a rules-based investor checklist covering endpoint, design, enrollment, and timeline. No jargon, no signup.
Translate a trial →What you get
Free tools for the basics. Pro for the catalyst decision.
We pull from ClinicalTrials.gov, SEC EDGAR, and FDA sources, then turn it into watchlists, risk flags, and investor checklists you can actually act on.
Catalyst calendar
Phase 3 readouts and FDA decisions we can trace to a primary source — each one dated, sourced, and explained in plain English.
Trial Translator
Paste any ClinicalTrials.gov ID. Get the endpoint, the design, and the investor checklist back in plain English — from live registry data.
Company profiles
Pipelines, bull and bear cases, and cash-runway context for the clinical-stage names most likely to move on a catalyst.
Biotech screener
Filter clinical-stage companies by therapeutic area, lead pipeline phase, and market cap. Free, no signup.
Learn biotech
From "what is a PDUFA date" to reading a survival curve without pretending you already can.
Weekly briefing
Every Sunday: the catalysts landing this week, what the bar is, and what would count as a miss. Free.
Explore by area
Therapeutic areas we cover
Company counts below are the profiles currently published in each area. Each one opens the screener filtered to that area.
How to judge us
The parts most sites leave out.
Biotech investing punishes false confidence. So does a research site that overstates what it knows. Here is what we commit to instead.
Sources are named
Trial data comes from ClinicalTrials.gov, filings from SEC EDGAR, decision dates from FDA. Company pages link the registry record.
AI drafts are labelled
Analysis drafted with AI assistance says so. Our editorial policy sets out what gets human review before it publishes.
We publish the limits
Dated content shows when it was last updated. Where our coverage is thin, the page says so rather than rounding up.
Read the methodology, the editorial policy, or our disclosures.
Subscribe
Stay ahead of the readout
Start with the free weekly briefing. Upgrade when you want the full ranked watchlist and risk flags.
Free catalyst calendar
$0/month
- Printable monthly catalyst calendar
- Weekly catalyst briefing
- Full catalyst calendar access
- Screener and Trial Translator
- All published guides and analysis
Free weekly biotech briefing. No spam. We only use this address for the briefing. By subscribing, you agree to our Privacy Policy and Terms.
ClinicalInvestor Pro
$19/month
or $199/year
- Everything in Free, plus:
- Full ranked monthly Catalyst Watchlist
- Trial, FDA, and financing risk flags
- Unlimited Trial Translator workflow
- Premium catalyst memos and memo archive
- Saved-watchlist and alert workflow roadmap
Pro checkout is not open yet — join the launch list for availability details.
Educational research only. No financial advice, and no recommendation to buy or sell any security. Free briefing — unsubscribe any time. Some affiliate links may earn compensation; see our disclosures.